Newsroom

HTG Molecular Diagnostics (HTGM) Launches Next-Gen Assay for Diffuse Large B-Cell Lymphomas

HTG Molecular Diagnostics, Inc,, a provider of instruments and reagents for molecular profiling applications, announced the availability of the HTG EdgeSeq Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin Assay (research use only). DLBCL, the most common form of non-Hodgkin’s lymphoma (NHL) in adults, is characterized by two major subtypes, activated B-cell-like (ABC) and germinal center B-cell-like (GCB). The HTG EdgeSeq DLBCL Cell of Origin Assay classifies DLBCL as ABC or GCB and was trained and validated on over 250 cases previously subtyped through microarray-based gene expression profiling. Automated on the HTG EdgeSeq system, the assay couples HTG’s proprietary nuclease protection chemistry with next-generation sequencing (NGS).

HTG Molecular Diagnostics (HTGM) Launches Next-Gen Assay for Diffuse Large B-Cell Lymphomas
Street Insider

How Health IT Integration Can Help Reduce Diagnostic Errors

An estimated 5 percent of U.S. adults who seek outpatient care each year experience a diagnostic error, according to a report published Sept. 23 by the Institute of Medicine (IOM). Such errors account for up to 17 percent of adverse errors in hospitals. The IOM study recommends looking broadly at improving the diagnostic process, in part by enhancing health IT interoperability and the flow of information across organizations.

How Health IT Integration Can Help Reduce Diagnostic Errors

Health IT Interoperability